VolitionRX Ltd VNRX 深 沪
等待开盘 05-14 09:30:00 美东时间
2.36
+0.040
+1.72%
华盛通- 最 高2.3695
- 今 开2.29
- 成交量 23.12万股
- 最 低 2.10
- 昨 收 2.32
- 总市值 1908.76万
- 52周最高 18.80
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.0114
- 委 比 -23.46%
- 总股本 808.80万
- 历史最高 185.60
- 量 比 0.55
- 振 幅 11.62%
- 历史最低 2.10
- 每 手 1
- 风险率 4.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多VolitionRx Submits Clinical Manuscript For Peer Review Over Its Nu.Q Vet Feline Prototype Assay To Trace Lymphoma In Cats
VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces submission for peer review a clinical manuscript1 reporting the high accuracy of its Nu.Q® Vet Feline prototype assay in
05-06 20:20
VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats
The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment HENDERSON, Nev., May 6, 2026 /PRNewswire/ -- VolitionRx...
05-06 20:17
D. Boral Capital Downgrades VolitionRX to Hold
D. Boral Capital analyst Jason Kolbert downgrades VolitionRX (AMEX:VNRX) from Buy to Hold.
04-20 20:41
VolitionRx Launches Online Store After 10 Years Of Research Into Cancer Testing Tools, Starts Selling Lab-Ready Nucleosome Products Online To Boost Research Use
VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the launch of its rNuQ webshop offering a range of reliable, ready to use recombinant nucleosomes that we have developed over
04-20 19:35
Volition Launches rNuQ™ Webshop Broadening Product Range
HENDERSON, Nev., April 20, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the launch of its rNuQ webshop offering...
04-20 19:30
美股大行评级 | 摩根大通上调霸王茶姬至"超配"，目标价上调至16美元；康尼格拉食品遭高盛、瑞银等7家机构下调目标价
今日重点评级关注：Leerink Partners：维持Camp4 Therapeutics"跑赢大市"评级，目标价从8美元升至9美元；韦德布什：维持Arcus Biosciences"跑赢大市"评级，目标价从37美元升至41美元
04-06 16:27
VolitionRx Earnings Call: Breakthroughs Amid Funding Strain
VolitionRX Ltd. (($VNRX)) has held its Q4 earnings call. Read on for the main h...
04-05 08:07
HC Wainwright & Co. Maintains Buy on VolitionRX, Lowers Price Target to $1
HC Wainwright & Co. analyst Yi Chen maintains VolitionRX (AMEX:VNRX) with a Buy and lowers the price target from $1.5 to $1.
04-03 00:06
VolitionRX Q4 EPS $(0.05), Inline, Sales $447.034K Miss $765.167K Estimate
VolitionRX (AMEX:VNRX) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This is a 16.67 percent increase over losses of $(0.06) per share from the same period last year. The
04-01 04:47
Earnings Scheduled For March 31, 2026
Companies Reporting Before The Bell • Bitfarms (NASDAQ:BITF) is projected to re...
03-31 19:11
